Anteris Raises $320M, Advances DurAVR Trial with US Patient Enrolment

Capital Raise Fuels Clinical and Manufacturing Scale-Up

Anteris Technologies Global Corp. (ASX:AVR, NASDAQ: AVR) entered 2026 with a substantial capital injection, completing a $320 million raise in January through a $230 million public offering and a $90 million private placement with Medtronic. This funding dramatically improved the company's liquidity, lifting its cash and equivalents from $12.6 million at the end of 2025 to $283.2 million by March 31, 2026. The proceeds are earmarked primarily for advancing the DurAVR Transcatheter Heart Valve (THV) pivotal PARADIGM Trial and expanding manufacturing capacity to support anticipated commercialisation.

The capital raise comes on the back of continued operational investment, with research and development expenses climbing 6% year-on-year to $17.5 million in Q1 2026. This increase reflects the scaling of manufacturing and quality systems, process validation, and expansion of the clinical team to support ongoing trial enrolment. The company is transitioning its production into new ISO-qualified clean rooms and diversifying its ADAPT® tissue supply between the US and Australia to mitigate supply chain risks.

PARADIGM Trial Advances with US Patient Enrolment

Recruitment in the global PARADIGM Trial, designed to evaluate the DurAVR THV against commercially available TAVR devices, is progressing steadily in Europe and now the United States. The trial aims to enrol approximately 1,000 patients in a randomized controlled design assessing a composite endpoint of mortality, stroke, and cardiovascular hospitalisation at one year. The recent US enrolment milestone was enabled by Medicare reimbursement eligibility secured under the Centers for Medicare & Medicaid Services (CMS) national coverage policy, a critical step to facilitate site activation and patient recruitment.

This momentum was underscored by the first US patients being enrolled and treated in May 2026, following regulatory approvals and site initiations. The CMS coverage is expected to accelerate operational momentum across US centers, supporting the trial’s timeline toward Premarket Approval (PMA) submission and anticipated CE Mark approval in Europe. The DurAVR valve’s biomimetic design, featuring the patented ADAPT® anti-calcification tissue technology, remains central to the company’s clinical and commercial strategy.

Operationally, Anteris is also expanding its physical footprint, having signed a long-term lease in Brooklyn Park, Minnesota, for approximately 181,000 square feet of office and warehouse space. This new facility is intended to support manufacturing scale-up and broader operational needs as the company prepares for commercialisation. The lease includes a rent abatement period and options for extension, reflecting a strategic investment in infrastructure aligned with the company’s growth trajectory.

Financial Performance and Outlook

Despite the operational advances, Anteris reported a net loss of $22.9 million for Q1 2026, slightly wider than the $21.9 million loss in the prior year period. Total revenues remained modest at $0.5 million, primarily from regenerative tissue product sales, reflecting the company’s development-stage status. Operating cash outflows increased to $28.7 million, driven by clinical trial activities and manufacturing investments.

The company’s balance sheet strengthened considerably post-capital raise, with stockholders’ equity swinging from a deficit of $253,000 at December 31, 2025, to a positive $278 million at quarter-end. Anteris expects its current cash runway to sustain operations for at least the next 12 months as it advances the PARADIGM Trial and prepares for regulatory submissions.

Internal controls remain an area of focus, with ongoing remediation efforts addressing previously identified material weaknesses. Management continues to enhance financial reporting processes and control environments, though full remediation and validation remain in progress.

Strategic Partnerships and Development Changes

In addition to the capital raise involving Medtronic, the company terminated its development agreement with v2vmedtech in April 2026, ceasing further funding obligations and paying a contractual break fee. This move refocuses resources on the DurAVR THV program and its pivotal trial execution.

Anteris’ clinical engagement continues with presentations of data from the EMBARK Study and the US Early Feasibility Study at recent cardiology conferences, maintaining scientific dialogue with the interventional cardiology community. These efforts complement the ongoing patient recruitment and site activations, supporting the company’s pathway to regulatory approval and commercial launch.

While the company’s financials reflect the typical profile of a development-stage medtech firm, the combination of a robust capital position, active clinical trial progress, and operational expansion positions Anteris to navigate the critical next phases of product validation and market entry.

Investors may note the company’s continued reliance on clinical trial success and regulatory approvals as pivotal catalysts, with the PARADIGM Trial’s enrolment pace and data releases likely to drive near-to-medium-term valuation inflections. The recently secured Medicare coverage and US enrolment commencement mark tangible progress in this regard, yet uncertainties inherent in clinical development and regulatory pathways remain.

As Anteris scales manufacturing and clinical operations, the new Minnesota lease underscores a commitment to infrastructure growth, though it also introduces additional fixed costs that will require careful management alongside ongoing R&D expenditures.

With a strengthened balance sheet and clear milestones ahead, Anteris stands at a critical juncture where execution on clinical and regulatory fronts will be closely watched by market participants.

The company’s recent activities build on its earlier capital raise and trial initiation milestones, including the first US patients enrolled and Medicare reimbursement eligibility, which have set the stage for this quarter’s developments.